Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00115245
Status:
COMPLETED
Last Update Posted:
2015-05-12
First Post:
2005-06-21
Brief Title:
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive Compensated Chronic Hepatitis B
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive Compensated Chronic Hepatitis B
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study is being conducted to compare the safety and effectiveness of the investigational medication LdT telbivudine versus adefovir dipivoxil a drug approved by the Food and Drug Administration FDA for the treatment of hepatitis B infection The results for patients taking LdT will be compared to results for patients taking adefovir dipivoxil
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None